Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Correction: The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance.

Hepburn AC, Steele RE, Veeratterapillay R, Wilson L, Kounatidou EE, Barnard A, Berry P, Cassidy JR, Moad M, El-Sherif A, Gaughan L, Mills IG, Robson CN, Heer R.

Oncogene. 2019 May;38(22):4425. doi: 10.1038/s41388-019-0826-2.

PMID:
31068666
2.

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.

Kounatidou E, Nakjang S, McCracken SRC, Dehm SM, Robson CN, Jones D, Gaughan L.

Nucleic Acids Res. 2019 Jun 20;47(11):5634-5647. doi: 10.1093/nar/gkz286.

3.

The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance.

Hepburn AC, Steele RE, Veeratterapillay R, Wilson L, Kounatidou EE, Barnard A, Berry P, Cassidy JR, Moad M, El-Sherif A, Gaughan L, Mills IG, Robson CN, Heer R.

Oncogene. 2019 May;38(22):4412-4424. doi: 10.1038/s41388-019-0712-y. Epub 2019 Feb 11. Erratum in: Oncogene. 2019 May 8;:.

4.

The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival.

McClurg UL, Azizyan M, Dransfield DT, Namdev N, Chit NCTH, Nakjang S, Robson CN.

Oncotarget. 2018 May 18;9(38):24992-25007. doi: 10.18632/oncotarget.25167. eCollection 2018 May 18.

5.

Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12.

McClurg UL, Chit NCTH, Azizyan M, Edwards J, Nabbi A, Riabowol KT, Nakjang S, McCracken SR, Robson CN.

Oncogene. 2018 Aug;37(34):4679-4691. doi: 10.1038/s41388-018-0283-3. Epub 2018 May 14.

PMID:
29755129
6.

Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein.

McClurg UL, Nabbi A, Ricordel C, Korolchuk S, McCracken S, Heer R, Wilson L, Butler LM, Irving-Hooper BK, Pedeux R, Robson CN, Riabowol KT, Binda O.

Br J Cancer. 2018 Mar 6;118(5):713-726. doi: 10.1038/bjc.2017.447. Epub 2018 Jan 30.

7.

Multipotent Basal Stem Cells, Maintained in Localized Proximal Niches, Support Directed Long-Ranging Epithelial Flows in Human Prostates.

Moad M, Hannezo E, Buczacki SJ, Wilson L, El-Sherif A, Sims D, Pickard R, Wright NA, Williamson SC, Turnbull DM, Taylor RW, Greaves L, Robson CN, Simons BD, Heer R.

Cell Rep. 2017 Aug 15;20(7):1609-1622. doi: 10.1016/j.celrep.2017.07.061.

8.

The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration.

Munkley J, McClurg UL, Livermore KE, Ehrmann I, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, Leung HY, Mills IG, Robson CN, Rajan P, Elliott DJ.

Sci Rep. 2017 Jul 12;7(1):5249. doi: 10.1038/s41598-017-05489-5.

9.

Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer.

Jones D, Noble M, Wedge SR, Robson CN, Gaughan L.

Sci Rep. 2017 Feb 16;7:40957. doi: 10.1038/srep40957.

10.

Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity.

McClurg UL, Cork DMW, Darby S, Ryan-Munden CA, Nakjang S, Mendes Côrtes L, Treumann A, Gaughan L, Robson CN.

Nucleic Acids Res. 2017 Feb 28;45(4):1793-1804. doi: 10.1093/nar/gkw1162.

11.

Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells.

Logan IR, McClurg UL, Jones DL, O'Neill DJ, Shaheen FS, Lunec J, Gaughan L, Robson CN.

Oncotarget. 2016 Nov 15;7(46):74724-74733. doi: 10.18632/oncotarget.12542.

12.

Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability.

Munkley J, Vodak D, Livermore KE, James K, Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries LW, Leung HY, Robson CN, Mills IG, Rajan P, Elliott DJ.

EBioMedicine. 2016 Jun;8:103-116. doi: 10.1016/j.ebiom.2016.04.018. Epub 2016 Apr 20.

13.

Mechanism of Histone H3K4me3 Recognition by the Plant Homeodomain of Inhibitor of Growth 3.

Kim S, Natesan S, Cornilescu G, Carlson S, Tonelli M, McClurg UL, Binda O, Robson CN, Markley JL, Balaz S, Glass KC.

J Biol Chem. 2016 Aug 26;291(35):18326-41. doi: 10.1074/jbc.M115.690651. Epub 2016 Jun 8.

14.

The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells.

Munkley J, Livermore KE, McClurg UL, Kalna G, Knight B, McCullagh P, McGrath J, Crundwell M, Leung HY, Robson CN, Harries LW, Rajan P, Elliott DJ.

Oncoscience. 2015 Sep 14;2(9):755-64. eCollection 2015.

15.

Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer.

McClurg UL, Harle VJ, Nabbi A, Batalha-Pereira A, Walker S, Coffey K, Gaughan L, McCracken SR, Robson CN.

Oncotarget. 2015 Nov 10;6(35):37724-36. doi: 10.18632/oncotarget.6075.

16.

The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer.

Munkley J, Oltean S, Vodák D, Wilson BT, Livermore KE, Zhou Y, Star E, Floros VI, Johannessen B, Knight B, McCullagh P, McGrath J, Crundwell M, Skotheim RI, Robson CN, Leung HY, Harries LW, Rajan P, Mills IG, Elliott DJ.

Oncotarget. 2015 Oct 27;6(33):34358-74. doi: 10.18632/oncotarget.6024.

17.

FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.

Jones D, Wade M, Nakjang S, Chaytor L, Grey J, Robson CN, Gaughan L.

Oncotarget. 2015 Oct 6;6(30):29782-94. doi: 10.18632/oncotarget.4927.

18.

The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7.

Stockley J, Markert E, Zhou Y, Robson CN, Elliott DJ, Lindberg J, Leung HY, Rajan P.

Sci Rep. 2015 Aug 27;5:13426. doi: 10.1038/srep13426.

19.

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.

O'Neill D, Jones D, Wade M, Grey J, Nakjang S, Guo W, Cork D, Davies BR, Wedge SR, Robson CN, Gaughan L.

Oncotarget. 2015 Sep 22;6(28):26029-40. doi: 10.18632/oncotarget.4347.

20.

Deubiquitinating enzymes as oncotargets.

McClurg UL, Robson CN.

Oncotarget. 2015;6(12):9657-68. Review.

21.

Using induced pluripotent stem cells as a tool for modelling carcinogenesis.

Curry EL, Moad M, Robson CN, Heer R.

World J Stem Cells. 2015 Mar 26;7(2):461-9. doi: 10.4252/wjsc.v7.i2.461. Review.

22.

Artificial Intelligence Systems as Prognostic and Predictive Tools in Ovarian Cancer.

Enshaei A, Robson CN, Edmondson RJ.

Ann Surg Oncol. 2015 Nov;22(12):3970-5. doi: 10.1245/s10434-015-4475-6. Epub 2015 Mar 10.

PMID:
25752894
23.

Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells.

Munkley J, Lafferty NP, Kalna G, Robson CN, Leung HY, Rajan P, Elliott DJ.

BMC Cancer. 2015 Jan 16;15:9. doi: 10.1186/s12885-015-1012-8.

24.

Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYC.

Romeo MM, Ko B, Kim J, Brady R, Heatley HC, He J, Harrod CK, Barnett B, Ratner L, Lairmore MD, Martinez E, Lüscher B, Robson CN, Henriksson M, Harrod R.

Virology. 2015 Feb;476:271-288. doi: 10.1016/j.virol.2014.12.008. Epub 2015 Jan 5.

25.

Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.

Rajan P, Stockley J, Sudbery IM, Fleming JT, Hedley A, Kalna G, Sims D, Ponting CP, Heger A, Robson CN, McMenemin RM, Pedley ID, Leung HY.

BMC Cancer. 2014 Dec 18;14:977. doi: 10.1186/1471-2407-14-977.

26.

The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.

Wade MA, Jones D, Wilson L, Stockley J, Coffey K, Robson CN, Gaughan L.

Nucleic Acids Res. 2015 Jan;43(1):196-207. doi: 10.1093/nar/gku1298. Epub 2014 Dec 8.

27.

The co-chaperone p23 promotes prostate cancer motility and metastasis.

Cano LQ, Lavery DN, Sin S, Spanjaard E, Brooke GN, Tilman JD, Abroaf A, Gaughan L, Robson CN, Heer R, Mauri F, de Rooij J, Driouch K, Bevan CL.

Mol Oncol. 2015 Jan;9(1):295-308. doi: 10.1016/j.molonc.2014.08.014. Epub 2014 Sep 6.

28.

Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway.

McClurg UL, Summerscales EE, Harle VJ, Gaughan L, Robson CN.

Oncotarget. 2014 Aug 30;5(16):7081-92.

29.

SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cells.

O'Neill DJ, Williamson SC, Alkharaif D, Monteiro IC, Goudreault M, Gaughan L, Robson CN, Gingras AC, Binda O.

Epigenetics. 2014 Jul;9(7):942-50. doi: 10.4161/epi.28864. Epub 2014 Apr 21.

30.

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.

Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010. Epub 2014 Apr 3.

31.

A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferation.

Munkley J, Rajan P, Lafferty NP, Dalgliesh C, Jackson RM, Robson CN, Leung HY, Elliott DJ.

Oncotarget. 2014 Jan 15;5(1):131-9.

32.

Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptor.

Burska UL, Harle VJ, Coffey K, Darby S, Ramsey H, O'Neill D, Logan IR, Gaughan L, Robson CN.

J Biol Chem. 2013 Nov 8;288(45):32641-50. doi: 10.1074/jbc.M113.485912. Epub 2013 Sep 21.

33.

Renal differentiation from adult spermatogonial stem cells.

Heer R, Hepburn AC, Williamson SC, Kennedy A, El-Sherif A, Soomro NA, Brown CD, Robson CN.

Ren Fail. 2013;35(10):1387-91. doi: 10.3109/0886022X.2013.828266. Epub 2013 Sep 2.

PMID:
23991628
34.

Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer.

Williamson SC, Mitter R, Hepburn AC, Wilson L, Mantilla A, Leung HY, Robson CN, Heer R.

Br J Cancer. 2013 Aug 20;109(4):950-6. doi: 10.1038/bjc.2013.399. Epub 2013 Jul 23.

35.

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.

Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, Dunkley TP, Brave SR, Broadbent N, Stratton NC, Trueman D, Mouchet E, Shaheen FS, Jacobs VN, Cumberbatch M, Wilson J, Jones RD, Bradbury RH, Rabow A, Gaughan L, Womack C, Barry ST, Robson CN, Critchlow SE, Wedge SR, Brooks AN.

Mol Cancer Ther. 2013 Sep;12(9):1715-27. doi: 10.1158/1535-7163.MCT-12-1174. Epub 2013 Jul 16.

36.

Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.

Townes CL, Ali A, Gross N, Pal D, Williamson S, Heer R, Robson CN, Pickard RS, Hall J.

Prostate. 2013 Oct;73(14):1529-37. doi: 10.1002/pros.22700. Epub 2013 Jul 1.

PMID:
23818154
37.

KDM4B is a master regulator of the estrogen receptor signalling cascade.

Gaughan L, Stockley J, Coffey K, O'Neill D, Jones DL, Wade M, Wright J, Moore M, Tse S, Rogerson L, Robson CN.

Nucleic Acids Res. 2013 Aug;41(14):6892-904. doi: 10.1093/nar/gkt469. Epub 2013 May 30.

38.

A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells.

Moad M, Pal D, Hepburn AC, Williamson SC, Wilson L, Lako M, Armstrong L, Hayward SW, Franco OE, Cates JM, Fordham SE, Przyborski S, Carr-Wilkinson J, Robson CN, Heer R.

Eur Urol. 2013 Nov;64(5):753-61. doi: 10.1016/j.eururo.2013.03.054. Epub 2013 Apr 6.

39.

The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.

Coffey K, Rogerson L, Ryan-Munden C, Alkharaif D, Stockley J, Heer R, Sahadevan K, O'Neill D, Jones D, Darby S, Staller P, Mantilla A, Gaughan L, Robson CN.

Nucleic Acids Res. 2013 Apr;41(8):4433-46. doi: 10.1093/nar/gkt106. Epub 2013 Feb 21.

40.

p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer.

Clark EL, Hadjimichael C, Temperley R, Barnard A, Fuller-Pace FV, Robson CN.

PLoS One. 2013;8(1):e54150. doi: 10.1371/journal.pone.0054150. Epub 2013 Jan 17.

41.

Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling.

Hepburn AC, Veeratterapillay R, Williamson SC, El-Sherif A, Sahay N, Thomas HD, Mantilla A, Pickard RS, Robson CN, Heer R.

PLoS One. 2012;7(11):e50690. doi: 10.1371/journal.pone.0050690. Epub 2012 Nov 30.

42.

Human α(2)β(1)(HI) CD133(+VE) epithelial prostate stem cells express low levels of active androgen receptor.

Williamson SC, Hepburn AC, Wilson L, Coffey K, Ryan-Munden CA, Pal D, Leung HY, Robson CN, Heer R.

PLoS One. 2012;7(11):e48944. doi: 10.1371/journal.pone.0048944. Epub 2012 Nov 7.

43.

Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer.

Coffey K, Blackburn TJ, Cook S, Golding BT, Griffin RJ, Hardcastle IR, Hewitt L, Huberman K, McNeill HV, Newell DR, Roche C, Ryan-Munden CA, Watson A, Robson CN.

PLoS One. 2012;7(10):e45539. doi: 10.1371/journal.pone.0045539. Epub 2012 Oct 8.

44.

Ubiquitin-based probes prepared by total synthesis to profile the activity of deubiquitinating enzymes.

de Jong A, Merkx R, Berlin I, Rodenko B, Wijdeven RH, El Atmioui D, Yalçin Z, Robson CN, Neefjes JJ, Ovaa H.

Chembiochem. 2012 Oct 15;13(15):2251-8. doi: 10.1002/cbic.201200497. Epub 2012 Sep 25.

45.

Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?

Bennett HL, Stockley J, Fleming JT, Mandal R, O'Prey J, Ryan KM, Robson CN, Leung HY.

BJU Int. 2013 Apr;111(4):672-82. doi: 10.1111/j.1464-410X.2012.11409.x. Epub 2012 Aug 16.

46.

Regulation of the androgen receptor by post-translational modifications.

Coffey K, Robson CN.

J Endocrinol. 2012 Nov;215(2):221-37. doi: 10.1530/JOE-12-0238. Epub 2012 Aug 7. Review.

PMID:
22872761
47.

Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome.

Rajan P, Dalgliesh C, Carling PJ, Buist T, Zhang C, Grellscheid SN, Armstrong K, Stockley J, Simillion C, Gaughan L, Kalna G, Zhang MQ, Robson CN, Leung HY, Elliott DJ.

PLoS One. 2011;6(12):e29088. doi: 10.1371/journal.pone.0029088. Epub 2011 Dec 14.

48.

Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.

Elattar A, Warburton KG, Mukhopadhyay A, Freer RM, Shaheen F, Cross P, Plummer ER, Robson CN, Edmondson RJ.

Gynecol Oncol. 2012 Jan;124(1):142-7. doi: 10.1016/j.ygyno.2011.09.004. Epub 2011 Oct 15.

PMID:
22001143
49.

Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer.

Armstrong K, Ahmad I, Kalna G, Tan SS, Edwards J, Robson CN, Leung HY.

Br J Cancer. 2011 Oct 25;105(9):1362-9. doi: 10.1038/bjc.2011.367. Epub 2011 Sep 27.

50.

In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells.

Blackwood JK, Williamson SC, Greaves LC, Wilson L, Rigas AC, Sandher R, Pickard RS, Robson CN, Turnbull DM, Taylor RW, Heer R.

J Pathol. 2011 Oct;225(2):181-8. doi: 10.1002/path.2965.

PMID:
21898876

Supplemental Content

Loading ...
Support Center